Stent thrombosis (ST) is a serious complication of coronary PCI. However, its incidence across registries is low. It has been classified according to onset into acute (less than 24 hrs.), subacute (between 24 and 30 days), late (between 30 and 365 days) and very late (later than 365 days). The estimated incidence of ST is...
EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory
Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early vascular recoil and late constrictive remodeling. Randomized studies have shown that the use of Paclitaxel drug eluting stents (DES) reduces the number of new revascularizations (even though these studies compared mostly against conventional balloons, which is why we...
Survey Stent-Save a Life! (SSL) / SOLACI | Procedural variation in the performance of Primary PCI
These last decades, primary percutaneous coronary intervention (PCI) has improved STEMI patient prognosis. However, its penetration varies across to regions and countries. As part of the initiative Stent-Save a Life! (SSL), SOLACI is publishing this electronic survey to assess the use of primary PCI throughout different countries based on the assumption that there is significant...
Clinical Results of IVUS-Guided Drug-Eluting Stent Implantation in Femoropopliteal Disease
Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that decrease the restenosis rate. Recently, the IMPERIAL study showed greater patency at 1 year and greater freedom from clinically guided revascularization at 2 years in favor of the ELUVIA stent (paclitaxel-eluting fluoropolymer, FP-DES) compared with the ZILVER PTX...
SOLACI-SOCIME 2022 | Advances in the design of STENTS in PCI: DIABETES MELLITUS – Dr. Roxana Mehran
Enjoy this master conference given by Dr. Roxana Mehran during the SOLACI-SOCIME 2022 Congress held at Expo Santa Fé, CDMX on August 4, 5 and 6, 2022. Topic: Advances in the design of STENTS in PCI: DIABETES MELLITUS.
Longitudinal Deformation of a Stent with the POT Technique
The fractal geometry of coronary bifurcations offers a mismatch between the proximal diameter of the main branch and the distal branches that make up the bifurcation. Angioplasty in this area can be performed through different techniques depending on plaque distribution, and the particular geometry of each bifurcation. Overall, and regardless of the strategy used, there...
Thin vs. Ultrathin Stents: 1-Year Clinical Results After IVUS/OCT-Guided Implantation
Second generation drug-eluting stents have lower frequency of thrombotic complications and in-stent restenosis. While clinical results have significantly improved, having a 2-3% annual rate of these complications within the first year after angioplasty is still worrisome. This resulted in the development of stents with struts <70 µm (ultrathin), with bioresorbable polymer and abluminal cover. Stents...
Three-Year Outcomes after CTA with 2-Stent Technique Vs. Provisional Stenting for Complex Bifurcation Lesions
The prevalence of coronary lesions with bifurcation involvement is about 20% in patients undergoing coronary angiography (CTA). While provisional stenting is overall the most accepted technique, the 2018 myocardial revascularization guidelines recommend the 2-stent technique for complex bifurcation lesions, defined as side branch with lesion >5mm, distal reference diameter of the side branch ≥2.75, or...
Two Safe Stents at Two Years in High Bleeding Risk
There is a consistent number of patients presenting high risk of bleeding. In this context, receiving dual antiplatelet therapy (DAPT) for 12 months would not be advisable. Even though the European and American guidelines recommend 1 to 6 months for chronic and acute syndromes in this group, these are often complex PCI cases, which makes...
Results of Zotarolimus-Eluting Stents vs Biolimus-Eluting Polymer-Free Stents After 2 Years. Are They Safe in Patients at High Risk for Bleeding?
The proportion of patients treated with coronary angioplasty who are at a high risk for bleeding is increasing. In this population, extended dual antithrombotic therapy increases the risk of bleeding. The 1-year randomized Onyx one study has demonstrated the non-inferiority of zotarolimus-eluting stents (ZES) vs. biolimus-coated polymer-free stent BioFreedom (DCS). Patients received dual-antiplatelet therapy (DAPT)...